Clinical trials: Affective Disorders
Major Depressive Disorder
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838681
- Testing
- Brexpiprazole, ADT
- Where
- 107 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,986 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Stress Disorders, Post-Traumatic
Optimizing Cognitive Remediation
Veterans with mental illness face challenges with community reintegration, including achieving vocational success, attaining their educational goals and going back to school, and maintaining a high quality of life.
- Conditions
- Schizophrenia, Stress Disorders, Post-Traumatic, Generalized Anxiety Disorder, Mood Disorders
- Trial name
- NCT04395157
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Office of Research and Development
Treatment Resistant Depression, Major Depressive Disorder
The UTHealth Ketamine Project
The primary objective of this study is to determine the effectiveness of serial infusions of intravenous (IV) ketamine in adults with treatment resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT02882711
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center, Houston
Bipolar Disorder, Bipolar I Disorder
Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder
This research study evaluates the effects of anFDA-approved medication NAC in individuals with Bipolar Disorder. Participants in the study will will be assigned to two medication conditions and will take both NAC and a matched…
- Conditions
- Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- NCT05340504
- Testing
- N-Acetyl cysteine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
- Trial name
- X-NOVA (NCT05376150)
- Testing
- XEN1101 10 mg, XEN1101 20 mg
- Where
- 20 sites in United States
- Volunteers
- 168 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Bipolar Disorder, Panic Disorder
Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD
The specific aim of this study is to evaluate the efficacy, tolerability, and safety of quetiapine SR monotherapy and divalproex sodium ER monotherapy in comparison to placebo in the treatment of ambulatory bipolar disorder with…
- Conditions
- Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
- Trial name
- NCT00579280
- Testing
- quetiapine SR, divalproex sodium ER
- Where
- 3 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Depression
Omega-3 for Depression and Other Cardiac Risk Factors - 2
The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to determine whether antidepressant augmentation with two grams of EPA omega-3 per day is superior to antidepressant therapy alone for…
- Trial name
- Omega-3(2) (NCT02021669)
- Testing
- Omega-3 supplement
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Washington University School of Medicine
Hyperlipidemia, Diabetes
Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome.
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Trial name
- NCT02029989
- Testing
- Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Schizophrenia, Schizoaffective Disorder
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
The purpose of this study is to learn how to help veterans play a stronger role in shaping their mental health care. Specifically we want to see if we can help veterans improve their mental health treatment by helping them decide…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression
- Trial name
- NCT00466323
- Testing
- Family Member Provider Outreach, Enhanced treatment as usual (e-TAU)
- Where
- 2 sites in United States
- Volunteers
- 238 people
- Sponsor
- US Department of Veterans Affairs
Bipolar Disorder
Aripiprazole in Children and Adolescents With Bipolar I Disorder
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
- Trial name
- NCT00110461
- Testing
- Aripiprazole
- Where
- 53 sites in United States
- Volunteers
- 296 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Treatment Resistant Depression (TRD)
Maintenance TMS in Treatment Resistant Depression
Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use.
- Trial name
- NCT06682299
- Testing
- Transmagnetic Stimulation, Electroconvulsive Therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Austin Messner
Major Depressive Disorder
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
Studies of the neural mechanisms underlying placebo effects in antidepressant clinical trials largely have been limited to demonstrating objective differences in brain activity between responders and non-responders to placebo.
- Trial name
- NCT01919216
- Testing
- Citalopram
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Cigarette Smoking, Schizophrenia
Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness
The overall aim of this study is to test the effect of academic detailing (i.e. provider-level educational intervention focused on evidence-based smoking cessation treatment for those with psychiatric illness) and community…
- Conditions
- Cigarette Smoking, Schizophrenia, Bipolar Disorder, Depressive Disorder, Major
- Trial name
- NCT02845440
- Testing
- Academic Detailing, Community Health Worker, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 1,165 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
Depression affects approximately 2.5% of children and 8% of adolescents. Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat…
- Trial name
- NCT00107120
- Testing
- Escitalopram
- Where
- 28 sites in United States
- Volunteers
- 312 people
- Sponsor
- Forest Laboratories
Bipolar Disorder
Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders
The primary aim of this proposal is to conduct a preliminary controlled trial of valproate and risperidone in children ages 3-7 yr. with bipolar disorders.
- Trial name
- NCT00221403
- Testing
- Risperidone oral solution, Valproate Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Depression, Bipolar
Depakote ER in Bipolar Depression
The purpose of this study is to examine the safety and efficacy of Depakote ER in bipolar depression and to evaluate metabolic and GABA changes with Depakote ER administration using PET and MRI/MRS brain imaging techniques.
- Trial name
- NCT00186186
- Testing
- Depakote ER
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Stanford University
Major Depression, Generalized Anxiety Disorder
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
The hypothesis of this study is that symptoms of anxiety, depression and insomnia; and indices of psychosocial function will all improve, while BZ use will decrease significantly during a twelve-week trial period of substituting…
- Trial name
- NCT01244711
- Testing
- quetiapine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder
Pilot Study of Duloxetine in Psychological Resilience
The purpose of this study is to explore benefits of duloxetine in enhancing psychological resilience and to understand the relevance of inhibiting of both serotonin (5HT) and norepinephrine (NE)to therapeutic responses.
- Trial name
- NCT00331799
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Mild Cognitive Impairment, Major Depressive Disorder
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Alzheimer's disease (AD), the most common dementing disorder of later life, is a major cause of disability and death in the elderly. Although a number of theoretical causes exist, the etiology of AD is still unknown.
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
- Trial name
- NCT01876823
- Testing
- es-citalopram, Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01377194
- Testing
- Levomilnacipran ER
- Where
- 51 sites in United States, Canada
- Volunteers
- 568 people
- Sponsor
- Forest Laboratories